Xiamen Innovax Biotech Co., Ltd. (“Innovax”), with a registered capital of RMB 1.2 billion, was founded in Mar, 2005. It is the key vaccine arm of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., and the only private-owned hightech enterprise engaged in vaccine research, development and production in Fujian Province.
Having been dedicated to the vaccine industry for nearly 20 years, Innovax is committed to providing high-quality, affordable and innovative vaccines for human being. With a sustainable industry-academia-research model, Innovax closely collaborated with the “National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD)” and established the world’s first E.coli platform for recombinant virus-like particle vaccines, and successfully launched the world’s first recombinant hepatitis E vaccine (Hecolin®) and the first HPV vaccine (Cecolin®) in the Chinese market. (the 4th HPV vaccine in the world).
Founded by Mr. Zhong Shanshan in 1993, Yangshengtang Co., Ltd. (“Yangshengtang”) is a modern high-tech enterprise specializing in the production and management of health products. After more than 20 years of development, the businesses of Yangshengtang have span into a wide range of industries such as soft drinks, food, biopharmaceuticals, cosmetics, pharmaceuticals, health care products and scientific research. Yangshengtang is committed to the sustainable development of the health industry, and strives to become a professional, first-class, cross-industry and large-scale national enterprise in China.
In September 2020, Nongfu Spring Co., Ltd., a subsidiary under Yangshengtang, was listed on the Stock Exchange of Hong Kong. Yangshengtang has been actively involved in the biopharmaceutical field since 1995, and in 2001 acquired Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, making it as the core enterprise in the biopharmaceutical field.
Founded in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (“Wantai Biological”) is a high-tech enterprise engaged in the R&D and production of biological diagnostic reagents and vaccines. As the main production base of HIV diagnostic reagents in Asia Pacific and well-known immunodiagnostic reagents in China, and the national new and high-tech base of model industrialization projects, Wantai Biological is the largest manufacturer of in vitro diagnostics, and also recognized in the industry as the first brand of immunodiagnostic products.
Wantai Biological has undertaken many scientific research projects under the National Science and Technology Major Project Against Infectious Disease, 863 Program and the 11th Five-Year Plan of the Ministry of Science and Technology. Its products cover multiple fields, such as ELISA test, colloidal gold test, chemiluminescence test, PCR test, biochemistry, vaccines and quality control materials and is committed to rapidly transforming research results to achieve industrialization.
闽公网安备 35020502000554号